Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
IPO Year: 1992
Exchange: NYSE
Website: teklacap.com/hql.html
| Date | Price Target | Rating | Analyst |
|---|
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSE:HQH), abrdn Life Sciences Investors (NYSE:HQL), abrdn Healthcare Opportunities Fund (NYSE:THQ), and abrdn World Healthcare Fund (NYSE:THW) (collectively, the "Funds") each, a closed-end management investment company, announced today the appointment of Dr. Jason Akus as co-lead portfolio manager to the Funds alongside Dr. Daniel Omstead. Dr. Akus has served on the investment team with Dr. Omstead for over 20 years.The Funds will continue to be managed in accordance with their existing investment objectives and strategies, pursuing the same investment philosophy and employing the same investment process that has
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
4 - abrdn Life Sciences Investors (0000884121) (Issuer)
SC 13D/A - abrdn Life Sciences Investors (0000884121) (Subject)
SC 13D/A - abrdn Life Sciences Investors (0000884121) (Subject)
SC 13D/A - abrdn Life Sciences Investors (0000884121) (Subject)
SC 13D/A - abrdn Life Sciences Investors (0000884121) (Subject)
SC 13D/A - abrdn Life Sciences Investors (0000884121) (Subject)
SC 13D - abrdn Life Sciences Investors (0000884121) (Subject)
SC 13G/A - TEKLA LIFE SCIENCES INVESTORS (0000884121) (Subject)
SC 13G/A - TEKLA LIFE SCIENCES INVESTORS (0000884121) (Subject)
N-CEN - abrdn Life Sciences Investors (0000884121) (Filer)
N-CSR - abrdn Life Sciences Investors (0000884121) (Filer)
N-PX - abrdn Life Sciences Investors (0000884121) (Filer)
N-CSRS - abrdn Life Sciences Investors (0000884121) (Filer)
NPORT-P - abrdn Life Sciences Investors (0000884121) (Filer)
DEFA14A - abrdn Life Sciences Investors (0000884121) (Filer)
DEF 14A - abrdn Life Sciences Investors (0000884121) (Filer)
NPORT-P - abrdn Life Sciences Investors (0000884121) (Filer)
N-CEN - abrdn Life Sciences Investors (0000884121) (Filer)
N-CSR - abrdn Life Sciences Investors (0000884121) (Filer)
PHILADELPHIA, PA / ACCESSWIRE / August 9, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP)(NYSE:ASGI)(NYSE:AWP)(NYSE:HQH)(NYSE:HQL)(NYSE:IFN)(NYSE:JEQ)(NYSE:THQ)(NYSE:THW)(NYSE:FAX)(NYSE:FCO)(NYSE:IAF)(NYSE:VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 30, 2024 to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equi
PHILADELPHIA, PA / ACCESSWIRE / June 28, 2024 / PHILADELPHIA, PA / ACCESSWIRE / June 28, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI)(NYSE:HQH)(NYSE:HQL)(NYSE:JEQ)(NYSE:THQ)(NYSE:THW)(NYSE:IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on June 28, 2024, on a per share basis to all shareholders of record as of June 21, 2024 (ex-dividend date June 21, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and abrdn Japan Equity Fund, Inc. (JEQ) which will pay on June 28, 2024, to al
PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSE:HQH), abrdn Life Sciences Investors (NYSE:HQL), abrdn Healthcare Opportunities Fund (NYSE:THQ), and abrdn World Healthcare Fund (NYSE:THW) (collectively, the "Funds") each, a closed-end management investment company, announced today the appointment of Dr. Jason Akus as co-lead portfolio manager to the Funds alongside Dr. Daniel Omstead. Dr. Akus has served on the investment team with Dr. Omstead for over 20 years.The Funds will continue to be managed in accordance with their existing investment objectives and strategies, pursuing the same investment philosophy and employing the same investment process that has
PHILADELPHIA, PA / ACCESSWIRE / February 9, 2024 / abrdn Life Sciences Investors (HQL), abrdn Healthcare Investors (HQH), and abrdn Healthcare Opportunities Fund (THQ) (collectively, the "Funds") each, a closed-end management investment company, announced today its Board of Trustees (each a "Board" and collectively, the "Boards") have approved an increase in each Fund's respective distribution rate and announce payment details for the Funds in the chart directly below.TickerExchangeFundDistribution Policy PreviousDistribution Policy NewDeclared DistributionAmountHQHNYSEabrdn Healthcare InvestorsAnnualized rate of 8% of rolling NAVAnnualized rate of 10% of rolling NAV$ 0.4800HQLNYSEabrdn Life
PHILADELPHIA, PA / ACCESSWIRE / January 10, 2024 / PHILADELPHIA, PA / ACCESSWIRE / January 10, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, IFN, JEQ))) (NYSE:HQH, HQL, IAF, THQ, THW))), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on January 10, 2024, on a per share basis to all shareholders of record as of December 29, 2023 (ex-dividend date December 28, 2023). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ)
HQH, HQL, THQ, THW Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manager to four NYSE listed healthcare and biotech thematic closed-end funds, totaling $2.8 bn in assets under management (AUM) as of October 26, 2023. In connection with the transaction, the Tekla team previously responsible for the management of the Funds has joined abrdn to form abrdn's healthcare and life sciences investment team. The Funds will continue to be managed in accordance with their existing investment objectives and strategies, by the same team of Boston-based
Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its four closed-end funds (the Funds). The Funds are: Tekla Healthcare Investors (HQH) Tekla Life Sciences Investors (HQL) Tekla Healthcare Opportunities Fund (THQ) Tekla World Healthcare Fund (THW) Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) approved the proposal at the Special Meetings held on October 25th, 2023. Tekla Healthcare Investors (HQH) and Tekla Life Sciences Investors (HQL) approved the proposal at the Special Meetings of Shareholders held previously on Oct
Tekla Healthcare Investors (HQH) today announced at the Special Meetings of shareholders ("Special Meetings") that the requisite vote had been attained for the proposal to approve the new investment advisory agreement with abrdn Inc. However, while the proposal has now been passed for both HQH and for Tekla Life Science Investors (HQL) at its meeting held on October 3rd, the new investment advisory agreement with abrdn Inc., and the related benefits that will accrue to shareholders as outlined below, cannot be implemented without approval by shareholders of all four Funds. Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) (the "Funds") still need additional
Tekla Life Sciences Investors (HQL) announced at the Joint Special Meetings of shareholders ("Special Meetings") that the requisite vote had been reached to approve the new investment advisory agreement with abrdn Inc. At the same Special Meetings, shareholders are voting with overwhelming support for the proposals, however, due to a lack of quorum, Tekla Healthcare Investors (HQH), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) (the "Funds") announced that their Special Meetings were adjourned once again until October 13, 2023 (HQH) and October 25, 2023 (THQ and THW), both at 9:00 a.m. EDT. As explained in the proxy statement, the new investment advisor
On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $44,305,054, of which $10,004,278 represents net unrealized appreciation of portfolio securities. The following table sets forth the estimated amounts of the current distribution, paid on September 29, 202
PHILADELPHIA, PA / ACCESSWIRE / August 9, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP)(NYSE:ASGI)(NYSE:AWP)(NYSE:HQH)(NYSE:HQL)(NYSE:IFN)(NYSE:JEQ)(NYSE:THQ)(NYSE:THW)(NYSE:FAX)(NYSE:FCO)(NYSE:IAF)(NYSE:VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 30, 2024 to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equi
PHILADELPHIA, PA / ACCESSWIRE / June 28, 2024 / PHILADELPHIA, PA / ACCESSWIRE / June 28, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI)(NYSE:HQH)(NYSE:HQL)(NYSE:JEQ)(NYSE:THQ)(NYSE:THW)(NYSE:IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on June 28, 2024, on a per share basis to all shareholders of record as of June 21, 2024 (ex-dividend date June 21, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and abrdn Japan Equity Fund, Inc. (JEQ) which will pay on June 28, 2024, to al
PHILADELPHIA, PA / ACCESSWIRE / February 9, 2024 / abrdn Life Sciences Investors (HQL), abrdn Healthcare Investors (HQH), and abrdn Healthcare Opportunities Fund (THQ) (collectively, the "Funds") each, a closed-end management investment company, announced today its Board of Trustees (each a "Board" and collectively, the "Boards") have approved an increase in each Fund's respective distribution rate and announce payment details for the Funds in the chart directly below.TickerExchangeFundDistribution Policy PreviousDistribution Policy NewDeclared DistributionAmountHQHNYSEabrdn Healthcare InvestorsAnnualized rate of 8% of rolling NAVAnnualized rate of 10% of rolling NAV$ 0.4800HQLNYSEabrdn Life
PHILADELPHIA, PA / ACCESSWIRE / January 10, 2024 / PHILADELPHIA, PA / ACCESSWIRE / January 10, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, IFN, JEQ))) (NYSE:HQH, HQL, IAF, THQ, THW))), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on January 10, 2024, on a per share basis to all shareholders of record as of December 29, 2023 (ex-dividend date December 28, 2023). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ)